Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > J Mov Disord > Volume 13(1); 2020 > Article
Erratum
 Modeling α-Synuclein Propagation with Preformed Fibril Injections
Hyun Kyung Chung1, Hoang-Anh Ho2, Dayana Pérez-Acuña1, Seung-Jae Lee1,3
Journal of Movement Disorders 2020;13(1):77-79.
DOI: https://doi.org/10.14802/jmd.19046.e
Published online: October 14, 2019

1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

2Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul, Korea

3Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea

Copyright © 2020 The Korean Movement Disorder Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev
  • 5,865 Views
  • 138 Download
  • 8 Web of Science
  • 8 Crossref
Full Article

Download PDF Download PDF

This corrects the article "Modeling α-Synuclein Propagation with Preformed Fibril Injections" on page 139.
J Mov Disord 2019;12(3):139-151.
In the original version of Table 1 associated with the review article “Modeling α-Synuclein Propagation with Preformed Fibril Injections”, the “amount of PFF injected” for the Rey et al. 2018 paper should be “0.8 μg of 5 mg/ml” instead of “8 μg 1 mg/ml”. The injection site mentioned in the “amount of PFFs injected” for Breid et al. 2016 paper should be “intraperitoneal” instead of “intramuscular”. The “amount of PFFs injected” for the Manfredsson et al. 2018 paper should be “6×5 μl” instead of “5 μg”. Additional information on the concentration of PFFs was added for Breid et al. 2016 paper and Durante et al. 2019 paper, being “1 μg/μl” and “1 mg/ml”, respectively.
In the first paragraph of the “SYNUCLEINOPATHIES IN PERIPHERAL PFF INJECTION MODELS” section, we included the description olfactory bulb injection. However, this content belongs to the “SYNUCLEINOPATHIES IN INTRACEREBRAL PFF INJECTION MODELS” section.
Table 1.
Injection methodologies from recent studies
Author Year Injection site Duration/Time point Model Amount of PFFs injected
Luk et al. [20] 2012 Somatosensory cortex and dorsal neostriatum 30 and 90 days post injection (p.i) M83 mice maintained on a C57BL/C3H background, α-syn -/- mice maintained on a C57BL/6 background 5 μg of 5 mg/mL human α-syn1-120Myc or WT full-length human α-syn per brain
Luk et al. [18] 2012 Striatum 30, 90, and 180 days p.i C57BL6/C3H F1, C57BL6/SJL F1, and CD1 mice 5 μg of 5 mg/mL full-length WT mouse α-syn per hemisphere
Masuda-Suzukake et al. [40] 2013 Substantia nigra 15 months p.i 4- to 6-month-old female C57BL/6J mice 10 µg of mouse or human α-syn PFFs
Guo et al. [60] 2013 Hippocampus 3, 6, and 9 months p.i 2- to 3-month-old PS19 mice or C57BL6/C3H F1 mice 5 μg of PFFs
Sacino et al. [49] 2014 Hippocampus 1, 2, and 4 months p.i 2-month-old M83 mice and M20 mice 2 μL of 2 mg/mL hfib 21–140 or Δ71–82 α-syn
Sacino et al. [27] 2014 Intramuscular (biceps femoris) 4, 8, and 12 months p.i 2-month-old M83 mice and M20 mice 10 μg of mouse PFFs, human 21–140 α-syn PFFs or Δ71–82 α-syn
Paumier et al. [48] 2015 Striatum 30, 60, and 180 days p.i Adult male Sprague-Dawley rats 8 μg of mouse or human α-syn PFFs
Osterberg et al. [39] 2015 Cortex 2, 3, and 4 months p.i 2- to 3-month-old α-syn-GFP mice 2.5 µL of 2 mg/mL mouse WT α-syn PFFs
Peelaerts et al. [57] 2015 Substantia nigra 4 months p.i Female Wistar rats 2 µL of 5 µg/µL α-syn PFFs (total of 10 µg)
Breid et al. [30] 2016 Peritoneum, tongue Up to 420 days p.i Tg (M83+/−:Gfap-luc+/−) and (Gfap-luc+/−) mice 5 μl (intraglossal) or 50 μl (intraperitoneal) of 1 ug/ul sonicated α-syn PFFs
Kim et al. [59] 2016 Striatum 3 and 6 months p.i 3-month-old C57BL/6J mice 5 μL of 10 μg/μL recombinant α-syn monomer, 2 μg/μL LPS(−) fibril seed, and 2 μg/μL LPS(+) fibril seed
Thakur et al. [45] 2017 Substantia nigra, ventral tegmental area 10 days p.i Female Sprague-Dawley rats 2.5 μL of full-length recombinant human α-syn PFFs (10 μg total) per site
Karampetsou, et al. [21] 2017 Striatum 60 days p.i 2- to 4-month-old male and female wild-type C57BL6/C3H mice and α-Syn-/- mice (C57BL6/JOlaHsd mice) 4.25 μg (4 μL) of three different types of human recombinant fibrillar α-syn
Abdelmotilib et al. [35] 2017 Striatum 6 months p.i 8- to 10-week-old mice and rats 10 μg (mice) or 20 μg (rats) of mouse or human α-syn PFFs
Blumenstock et al. [43] 2017 Dorsal striatum 30, 60, and 90 days p.i; 5 and 9 months p.i 2-month-old mice 5 μL (25 μg) of mouse α-syn PFFs
Sorrentino et al. [56] 2017 IC or CPu 4–5 months p.i 4-month-old M20 non-Tg (NTG) mice 2 μL of 2 mg/mL human or mouse WT α-syn PFFs
Harms et al. [63] 2017 Substantia nigra 1, 3, and 6 months p.i 8- to 10-week old Sprague-Dawley rats 8 μg of mouse α-syn PFFs
Shimozawa et al. [50] 2017 Caudate and putamen 3 months p.i 26-month-old marmosets 50 μL aliquots of 4 mg/mL mouse α-syn PFFs
Okuzumi et al. [44] 2018 Striatum 1 week pi, 0.75, 1.5, 3, and 6 months p.i 2- to 3-month-old C57BL/6J mice 5 μg/2.5 μL of recombinant mouse or human α-syn PFFs
Rey et al. [29] 2018 Olfactory bulb 1, 2, 3, 6, 9, 12, 18, and 23 months p.i 3-month-old female C57BL/6J mice 0.8 μl of 5 mg/ml WT mouse or human α-syn PFFs
Uemura et al. [28] 2018 Mouse gastric wall 45 days p.i 2-month-old male C57BL/6J mice 3 μL of 2 μg/μL mouse α-syn PFFs
Duffy et al. [47] 2018 Striatum 6 months p.i 2-month-old male Fischer mice 2 μL of 2 μg/μL mouse α-syn PFFs (unilateral)
Sorrentino et al. [42] 2018 Muscle 1, 2, 3, and 4 months p.i 2-month-old M83+/- mice 2,5, or 10 μg of mouse α-syn fibrils
Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT
Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT or truncated α-syn PFFs
Ayers et al. [54] 2018 Sciatic nerve (unilateral) 1, 2, and 4 months p.i and end-stage M83 and M20 mice 2 μL of 2 mg/mL mouse WT or human Δ71–82 α-syn PFFs
Manfredsson et al. [55] 2018 Enteric neurons of the descending colon 1, 6, and 12 months p.i Young adult male Sprague-Dawley rats 6×5 µl of 2 μg/μl mouse or human α-syn PFFs
Manfredsson et al. [55] 2018 Colon and stomach 12 months p.i Non-human primates (Macaca fascicularis) 10 injections of 10 µL (2 µg/µL)
Peralta Ramos et al. [68] 2019 Vein 12 hours p.i 2-month-old C57BL/6 mice 5 μg of Atto 488-labeled α-syn fibrils or ribbons
Durante et al. [77] 2019 Striatum 6, 7 weeks p.i Male Wistar rats 1 µL of 1 mg/ml human α-syn PFFs per site

The table describes the sites of preformed fibril (PFF) injection, the ages of the animals, the amount of seed, and the duration or time points sample analysis used in the experiments. WT: wild type, GFP: green fluorescent protein, LPS: lipopolysaccharide, IC: inferior colliculus, CPu: caudate putamen, NTG: non-Tg.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Experimental models of Parkinson's disease: Challenges and Opportunities
      Roshan Lal, Aditi singh, Shivam watts, Kanwaljit Chopra
      European Journal of Pharmacology.2024; 980: 176819.     CrossRef
    • Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers
      Shenjie Wu, Nancy C Hernandez Villegas, Daniel W Sirkis, Iona Thomas-Wright, Richard Wade-Martins, Randy Schekman
      eLife.2023;[Epub]     CrossRef
    • Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease
      Rui Huang, Yuyuan Gao, Qingrui Duan, Qingxi Zhang, Peikun He, Jianing Chen, Guixian Ma, Limin Wang, Yuhu Zhang, Kun Nie, Lijuan Wang
      Molecular Neurobiology.2023; 60(2): 979.     CrossRef
    • Impaired dopamine release in Parkinson’s disease
      Kaitlyn M L Cramb, Dayne Beccano-Kelly, Stephanie J Cragg, Richard Wade-Martins
      Brain.2023; 146(8): 3117.     CrossRef
    • Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets
      Smrithi Padmakumar, Praveen Kulkarni, Craig F. Ferris, Benjamin S. Bleier, Mansoor M. Amiji
      Biomedicine & Pharmacotherapy.2022; 149: 112812.     CrossRef
    • Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound
      Rodrigo Tomas-Grau, Florencia González-Lizárraga, Diego Ploper, César L. Avila, Sergio B. Socías, Pierre Besnault, Aurore Tourville, Rosa M. Mella, Patricia Villacé, Clarisa Salado, Clémence Rose, Blandine Seon-Méniel, Jean-Michel Brunel, Laurent Ferrié,
      Cells.2022; 11(17): 2759.     CrossRef
    • Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction
      Renee C Gentzel, Dawn Toolan, Sarah Jinn, Joel B Schachter, Lei Ma, Philipp J Kahle, Sean M Smith, Jacob N Marcus
      Neurobiology of Aging.2021; 106: 12.     CrossRef
    • Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson’s Disease Risk
      Alix Booms, Gerhard A. Coetzee
      Frontiers in Cellular Neuroscience.2021;[Epub]     CrossRef

    Comments on this article

    Add a comment
    Modeling α-Synuclein Propagation with Preformed Fibril Injections
    Modeling α-Synuclein Propagation with Preformed Fibril Injections
    Author Year Injection site Duration/Time point Model Amount of PFFs injected
    Luk et al. [20] 2012 Somatosensory cortex and dorsal neostriatum 30 and 90 days post injection (p.i) M83 mice maintained on a C57BL/C3H background, α-syn -/- mice maintained on a C57BL/6 background 5 μg of 5 mg/mL human α-syn1-120Myc or WT full-length human α-syn per brain
    Luk et al. [18] 2012 Striatum 30, 90, and 180 days p.i C57BL6/C3H F1, C57BL6/SJL F1, and CD1 mice 5 μg of 5 mg/mL full-length WT mouse α-syn per hemisphere
    Masuda-Suzukake et al. [40] 2013 Substantia nigra 15 months p.i 4- to 6-month-old female C57BL/6J mice 10 µg of mouse or human α-syn PFFs
    Guo et al. [60] 2013 Hippocampus 3, 6, and 9 months p.i 2- to 3-month-old PS19 mice or C57BL6/C3H F1 mice 5 μg of PFFs
    Sacino et al. [49] 2014 Hippocampus 1, 2, and 4 months p.i 2-month-old M83 mice and M20 mice 2 μL of 2 mg/mL hfib 21–140 or Δ71–82 α-syn
    Sacino et al. [27] 2014 Intramuscular (biceps femoris) 4, 8, and 12 months p.i 2-month-old M83 mice and M20 mice 10 μg of mouse PFFs, human 21–140 α-syn PFFs or Δ71–82 α-syn
    Paumier et al. [48] 2015 Striatum 30, 60, and 180 days p.i Adult male Sprague-Dawley rats 8 μg of mouse or human α-syn PFFs
    Osterberg et al. [39] 2015 Cortex 2, 3, and 4 months p.i 2- to 3-month-old α-syn-GFP mice 2.5 µL of 2 mg/mL mouse WT α-syn PFFs
    Peelaerts et al. [57] 2015 Substantia nigra 4 months p.i Female Wistar rats 2 µL of 5 µg/µL α-syn PFFs (total of 10 µg)
    Breid et al. [30] 2016 Peritoneum, tongue Up to 420 days p.i Tg (M83+/−:Gfap-luc+/−) and (Gfap-luc+/−) mice 5 μl (intraglossal) or 50 μl (intraperitoneal) of 1 ug/ul sonicated α-syn PFFs
    Kim et al. [59] 2016 Striatum 3 and 6 months p.i 3-month-old C57BL/6J mice 5 μL of 10 μg/μL recombinant α-syn monomer, 2 μg/μL LPS(−) fibril seed, and 2 μg/μL LPS(+) fibril seed
    Thakur et al. [45] 2017 Substantia nigra, ventral tegmental area 10 days p.i Female Sprague-Dawley rats 2.5 μL of full-length recombinant human α-syn PFFs (10 μg total) per site
    Karampetsou, et al. [21] 2017 Striatum 60 days p.i 2- to 4-month-old male and female wild-type C57BL6/C3H mice and α-Syn-/- mice (C57BL6/JOlaHsd mice) 4.25 μg (4 μL) of three different types of human recombinant fibrillar α-syn
    Abdelmotilib et al. [35] 2017 Striatum 6 months p.i 8- to 10-week-old mice and rats 10 μg (mice) or 20 μg (rats) of mouse or human α-syn PFFs
    Blumenstock et al. [43] 2017 Dorsal striatum 30, 60, and 90 days p.i; 5 and 9 months p.i 2-month-old mice 5 μL (25 μg) of mouse α-syn PFFs
    Sorrentino et al. [56] 2017 IC or CPu 4–5 months p.i 4-month-old M20 non-Tg (NTG) mice 2 μL of 2 mg/mL human or mouse WT α-syn PFFs
    Harms et al. [63] 2017 Substantia nigra 1, 3, and 6 months p.i 8- to 10-week old Sprague-Dawley rats 8 μg of mouse α-syn PFFs
    Shimozawa et al. [50] 2017 Caudate and putamen 3 months p.i 26-month-old marmosets 50 μL aliquots of 4 mg/mL mouse α-syn PFFs
    Okuzumi et al. [44] 2018 Striatum 1 week pi, 0.75, 1.5, 3, and 6 months p.i 2- to 3-month-old C57BL/6J mice 5 μg/2.5 μL of recombinant mouse or human α-syn PFFs
    Rey et al. [29] 2018 Olfactory bulb 1, 2, 3, 6, 9, 12, 18, and 23 months p.i 3-month-old female C57BL/6J mice 0.8 μl of 5 mg/ml WT mouse or human α-syn PFFs
    Uemura et al. [28] 2018 Mouse gastric wall 45 days p.i 2-month-old male C57BL/6J mice 3 μL of 2 μg/μL mouse α-syn PFFs
    Duffy et al. [47] 2018 Striatum 6 months p.i 2-month-old male Fischer mice 2 μL of 2 μg/μL mouse α-syn PFFs (unilateral)
    Sorrentino et al. [42] 2018 Muscle 1, 2, 3, and 4 months p.i 2-month-old M83+/- mice 2,5, or 10 μg of mouse α-syn fibrils
    Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
    Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT
    Milanese et al. [41] 2018 Striatum 4 months p.i C57BL/6 mice 5 μg (2.5 μL) of human α-syn PFFs
    Terada et al. [46] 2018 Striatum 3 months p.i 10-week-old C57BL/6J mice 5 μL (150 μM) of human WT or truncated α-syn PFFs
    Ayers et al. [54] 2018 Sciatic nerve (unilateral) 1, 2, and 4 months p.i and end-stage M83 and M20 mice 2 μL of 2 mg/mL mouse WT or human Δ71–82 α-syn PFFs
    Manfredsson et al. [55] 2018 Enteric neurons of the descending colon 1, 6, and 12 months p.i Young adult male Sprague-Dawley rats 6×5 µl of 2 μg/μl mouse or human α-syn PFFs
    Manfredsson et al. [55] 2018 Colon and stomach 12 months p.i Non-human primates (Macaca fascicularis) 10 injections of 10 µL (2 µg/µL)
    Peralta Ramos et al. [68] 2019 Vein 12 hours p.i 2-month-old C57BL/6 mice 5 μg of Atto 488-labeled α-syn fibrils or ribbons
    Durante et al. [77] 2019 Striatum 6, 7 weeks p.i Male Wistar rats 1 µL of 1 mg/ml human α-syn PFFs per site
    Table 1. Injection methodologies from recent studies

    The table describes the sites of preformed fibril (PFF) injection, the ages of the animals, the amount of seed, and the duration or time points sample analysis used in the experiments. WT: wild type, GFP: green fluorescent protein, LPS: lipopolysaccharide, IC: inferior colliculus, CPu: caudate putamen, NTG: non-Tg.

    Table 1.

    JMD : Journal of Movement Disorders Twitter
    © The Korean Movement Disorder Society.
    Close layer
    TOP